lirafugratinib (RLY-4008) / HLB Bio Group 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lirafugratinib (RLY-4008) / HLB Bio Group
2020-004535-24: A study to investigate the effects of study drug RLY-4008 in patients with Intrahepatic Cholangiocarcinoma and other Advanced Solid Tumors

Not yet recruiting
1/2
550
Europe
RLY-4008, RLY-4008, Capsule
Relay Therapeutics, Inc., Relay Therapeutics, Inc.
Unresectable or metastatic cholangiocarcinoma (CCA), other advanced solid tumors with an FGFR2-alteration or other potential FGFR2-dependent tumors, Cholangiocarcinoma (CCA) and Other Advanced Solid Tumors, Diseases [C] - Cancer [C04]
 
 
ReFocus, NCT04526106 / 2020-004535-24: REFOCUS: a First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with ICC and Other Advanced Solid Tumors

Active, not recruiting
1/2
490
Europe, US, RoW
RLY-4008
Elevar Therapeutics, Relay Therapeutics, Inc.
FGFR2 Amplification, FGFR2 Gene Mutation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Translocation, FGFR2 Gene Activation, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Other Solid Tumors, Adult
09/24
12/27

Download Options